Published in BMJ on September 21, 1996
Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. BMJ (1999) 4.94
Applying the results of clinical trials to patients to general practice: perceived problems, strengths, assumptions, and challenges for the future. Br J Gen Pract (1998) 1.88
Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2014) 1.76
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J (2009) 1.62
Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol (2010) 1.53
Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis--funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy. Crit Care (2008) 1.10
Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 1.03
Single- versus two- layer intestinal anastomosis: a meta-analysis of randomized controlled trials. BMC Surg (2006) 1.01
Statins for primary prevention: at what coronary risk is safety assured? Br J Clin Pharmacol (2001) 0.98
'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics (2006) 0.93
Growing pains of meta-analysis. BMJ (1996) 0.91
Manufacturers affect clinical results of THA with zirconia heads: a systematic review. Clin Orthop Relat Res (2009) 0.85
Factors explaining the heterogeneity of effects of patient decision aids on knowledge of outcome probabilities: a systematic review sub-analysis. Syst Rev (2013) 0.84
A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. Gut (2004) 0.84
Effect model law: an approach for the implementation of personalized medicine. J Pers Med (2013) 0.81
The evidence base for diabetes technology: appropriate and inappropriate meta-analysis. J Diabetes Sci Technol (2013) 0.79
Relation between treatment benefit and underlying risk in meta-analysis. Standard of "label invariance" should not be abandoned. BMJ (1996) 0.75
Commentary: On Effect Measures, Heterogeneity, and the Laws of Nature. Epidemiology (2015) 0.75
Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models. Stat Med (2016) 0.75
Individual patient data meta-analysis : Cervical stitch (cerclage) for preventing pregnancy loss in women. BMC Pregnancy Childbirth (2005) 0.75
A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA (1992) 22.27
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet (1994) 11.37
Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet (1995) 9.14
Regression towards the mean. BMJ (1994) 6.57
Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ (1993) 6.23
Who benefits from medical interventions? BMJ (1994) 5.58
Meta-analysis in clinical research. Ann Intern Med (1987) 5.16
An evidence based approach to individualising treatment. BMJ (1995) 5.10
A random-effects regression model for meta-analysis. Stat Med (1995) 4.83
Some examples of regression towards the mean. BMJ (1994) 4.01
Can overall results of clinical trials be applied to all patients? Lancet (1995) 3.69
Why sources of heterogeneity in meta-analysis should be investigated. BMJ (1994) 3.68
Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens (1995) 2.40
Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Stat Med (1992) 2.17
A bivariate approach to meta-analysis. Stat Med (1993) 1.90
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med (1993) 1.65
Methods for assessing whether change depends on initial value. Stat Med (1988) 1.61
"The challenge of meta-analysis": discussion. Indications and contra-indications for meta-analysis. J Clin Epidemiol (1995) 1.60
An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol (1993) 1.37
Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Stat Med (1994) 1.33
Problems induced by meta-analyses. Stat Med (1991) 1.23
Risks and benefits of treating mild hypertension: a misleading meta-analysis? J Hypertens (1995) 1.07
"Large-scale randomized evidence: large, simple trials and overviews of trials": discussion. A clinician's perspective on meta-analyses. J Clin Epidemiol (1995) 0.86
Desmopressin and blood loss after cardiac surgery. Lancet (1993) 0.81
Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 211.50
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA (1995) 45.41
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet (2001) 31.74
Measuring agreement in method comparison studies. Stat Methods Med Res (1999) 31.11
Multiple significance tests: the Bonferroni method. BMJ (1995) 23.46
Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ (2001) 20.65
Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) (1986) 18.51
Analysis of serial measurements in medical research. BMJ (1990) 16.69
Cronbach's alpha. BMJ (1997) 13.79
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ (1994) 11.85
The scandal of poor medical research. BMJ (1994) 11.58
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med (2001) 11.48
Statistical guidelines for contributors to medical journals. Br Med J (Clin Res Ed) (1983) 10.90
Statistics notes. Logarithms. BMJ (1996) 10.56
The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet (2002) 10.52
Statistics in medical journals. Stat Med (1983) 9.80
Evaluating non-randomised intervention studies. Health Technol Assess (2003) 9.69
Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet (1995) 9.14
Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ (2001) 8.98
Statistics and ethics in medical research: III How large a sample? Br Med J (1980) 8.78
Detecting and describing heterogeneity in meta-analysis. Stat Med (1998) 8.44
Better reporting of randomised controlled trials: the CONSORT statement. BMJ (1996) 8.39
More informative abstracts revisited. Ann Intern Med (1990) 8.26
Transforming data. BMJ (1996) 6.78
Regression towards the mean. BMJ (1994) 6.57
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet (1986) 6.51
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol (1987) 6.20
Measurement error. BMJ (1996) 6.18
Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA (1994) 5.80
Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion (1999) 5.67
Assessing possible hazards of reducing serum cholesterol. BMJ (1994) 5.61
Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet (2000) 5.61
Statistics notes. The odds ratio. BMJ (2000) 5.61
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol (2001) 5.43
Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol (2003) 5.40
How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing. Lancet (1999) 5.27
Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ (1996) 5.18
Correlation, regression, and repeated data. BMJ (1994) 4.88
Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjects. BMJ (1995) 4.87
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med (2000) 4.81
Social factors and height of primary schoolchildren in England and Scotland. J Epidemiol Community Health (1978) 4.73
Randomisation. BMJ (1991) 4.66
Patients' preferences and randomised trials. Lancet (1996) 4.64
Incidence and aetiology of heart failure; a population-based study. Eur Heart J (1999) 4.56
Measurement error and correlation coefficients. BMJ (1996) 4.38
Indirect comparisons of competing interventions. Health Technol Assess (2005) 4.33
Statistical aspects of prognostic factor studies in oncology. Br J Cancer (1994) 4.22
Measurement error. BMJ (1996) 4.13
Survival analysis part I: basic concepts and first analyses. Br J Cancer (2003) 4.08
Does breathing other people's tobacco smoke cause lung cancer? Br Med J (Clin Res Ed) (1986) 4.06
Some examples of regression towards the mean. BMJ (1994) 4.01
Survival probabilities (the Kaplan-Meier method). BMJ (1998) 3.98
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol (2007) 3.84
A catalogue of reporting guidelines for health research. Eur J Clin Invest (2010) 3.83
Seasonal variation in arterial blood pressure. Br Med J (Clin Res Ed) (1982) 3.82
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ (1998) 3.71
Effects of a drug overdose in a television drama on presentations to hospital for self poisoning: time series and questionnaire study. BMJ (1999) 3.52
Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. BMJ (2011) 3.50
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Transformations, means, and confidence intervals. BMJ (1996) 3.42
Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ (1995) 3.35
Measurement error proportional to the mean. BMJ (1996) 3.34
Haemostatic function and cardiovascular death: early results of a prospective study. Lancet (1980) 3.25
National study of health and growth: standards of attained height, weight and triceps skinfold in English children 5 to 11 years old. Ann Hum Biol (1977) 3.23
The use of transformation when comparing two means. BMJ (1996) 3.22
A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput Biol Med (1990) 3.18
Interaction 3: How to examine heterogeneity. BMJ (1996) 3.17
Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer (2004) 3.15
Survival analysis part II: multivariate data analysis--an introduction to concepts and methods. Br J Cancer (2003) 3.06
Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjects. BMJ (1995) 2.94
Randomised trial of educational visits to enhance use of systematic reviews in 25 obstetric units. BMJ (1998) 2.94
Survival of patients with a new diagnosis of heart failure: a population based study. Heart (2000) 2.86
Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med (2002) 2.86
Outcome selection bias in meta-analysis. Stat Methods Med Res (2005) 2.86
Statistics and ethics in medical research. VI--Presentation of results. Br Med J (1980) 2.85
The effects of combining education and enforcement to reduce tobacco sales to minors. A study of four northern California communities. JAMA (1991) 2.77
A prognostic model for ovarian cancer. Br J Cancer (2001) 2.77
Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med (2002) 2.73
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Podiatr Med Assoc (2001) 2.71
Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J Cancer (2003) 2.71
Baseline comparisons in randomized clinical trials. Stat Med (1991) 2.69
Predictors of physician's smoking cessation advice. JAMA (1991) 2.66
More informative abstracts. Ann Intern Med (1987) 2.63
Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet (2001) 2.61
One and two sided tests of significance. BMJ (1994) 2.61
A likelihood approach to meta-analysis with random effects. Stat Med (1996) 2.54
Hospitalization of patients with heart failure: a population-based study. Eur Heart J (2002) 2.54
Change in coronary risk and coronary risk factor levels in couples following lifestyle intervention. The British Family Heart Study. Arch Fam Med (1997) 2.41
Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet (2001) 2.35
Age at last full-term pregnancy and risk of breast cancer. Lancet (1993) 2.34
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
The efficacy of problem-solving treatments after deliberate self-harm: meta-analysis of randomized controlled trials with respect to depression, hopelessness and improvement in problems. Psychol Med (2001) 2.22